- Home
- KROS vs EU Comparison
KROS vs EU Comparison
Compare KROS & EU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KROS | EU |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Metals and Minerals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 655.9M | 503.7M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | KROS | EU |
|---|---|---|
| Price | $20.13 | $2.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 1 |
| Target Price | ★ $22.20 | $4.00 |
| AVG Volume (30 Days) | 969.1K | ★ 2.4M |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.57 | N/A |
| Revenue | ★ $246,718,000.00 | $44,142,000.00 |
| Revenue This Year | $6,876.34 | $22.24 |
| Revenue Next Year | N/A | $86.15 |
| P/E Ratio | $13.23 | ★ N/A |
| Revenue Growth | ★ 37798.31 | N/A |
| 52 Week Low | $9.12 | $1.01 |
| 52 Week High | $22.55 | $4.19 |
Technical Indicators
Market Signals| Indicator | KROS | EU |
|---|---|---|
| Relative Strength Index (RSI) | 56.99 | 37.74 |
| Support Level | $20.73 | $2.28 |
| Resistance Level | $21.75 | $2.46 |
| Average True Range (ATR) | 1.05 | 0.18 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 57.41 | 6.92 |
Price Performance
Historical ComparisonAbout KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About EU enCore Energy Corp.
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties of uranium resource properties in the United States. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's Projects are South Texas Operations, Dewey-Burdock Project, Gas Hills Project, Crownpoint & Hosta Butte Project, PFN (Prompt Fission Neutron) Technology, and Other Assets.